X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration draws on Aktis' proprietary radiopharmaceutical platform together with Lilly's expertise in oncology drug development and commercialization, with the goal of developing first-in-class and differentiated therapeutics for a range of solid tumors.
Lead Product(s): Radiopharmaceutical-based Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $1,160.0 million Upfront Cash: $60.0 million
Deal Type: Collaboration May 21, 2024
Details:
The additional funding will fuel the advancement of the miniprotein programs into the clinic and enable further investment in the differentiated development capabilities as well as end-to-end supply chain and distribution strategy.
Lead Product(s): Radiopharmaceutical Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Cowen Healthcare
Deal Size: $161.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing August 25, 2022
Details:
The agreement provide Aktis with a portfolio of suppliers that utilize varied techniques to produce high quality Actinium-225, and enhance the Company’s ability to ensure delivery of finished targeted radioconjugates to healthcare providers for administration to patients.
Lead Product(s): Actinium-225 Conjugated Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: NorthStar Medical Radioisotopes
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement August 23, 2022
Details:
Aktis Oncology is developing novel alpha radiotherapies to improve upon the efficacy of conventional solid tumor therapies, while limiting toxicity.
Lead Product(s): Alpha Radio Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Small molecule
Partner/Sponsor/Collaborator: EcoR1 Capital
Deal Size: $72.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing March 18, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
